Form D · Pharmaceuticals
Clene Nanomedicine, Inc.
Salt Lake City, UT · CIK 0001817741
Offering snapshot reported Aug 24, 2020 · SEC filing
- Reported sold
- $42.5M Offering amount: $46.2M
- Investors reported
- 61 Form D · investor count
- Minimum accepted
- $10K Reported outside-investor minimum
- First sale
- Aug 10, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 24, 2020 | Initial | $42,540,574 | No comparison | 61 | SEC filing |
| Jul 13, 2020 | Initial | $6,124,988 | No comparison | 12 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $949K (estimated)
- Finders' fees
- $0
- Form D file number
- 021-373923
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Crewe Capital, LLC | 152527 |
Source: Form D, filed Aug 24, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Rob Etherington | Director, Executive |
| Robert Gay | Director |
| Shalom Jacobovitz | Director |
| David Lisonbee | Director |
| Ryan Lund | Director |
| Alison Mosca | Director |
| John Stevens | Director |
| Reed Wilcox | Director |
| Chad Young | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
6550 South Millrock Drive, Suite G50
Salt Lake City, UT, 84121
Salt Lake City, UT, 84121